{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:37:58Z","timestamp":1772249878496,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    Baseline presence of nonstructural protein 5A (NS5A) resistance-associated variants can attenuate the efficacy of new direct-acting antivirals. A potential method to attain the higher efficacy would be to screen for NS5A polymorphisms prior to the initiation of therapy and to adjust the treatment length based on the test results. However, baseline testing adds additional costs and it is unclear whether this would represent a high value strategy for chronic hepatitis C in China.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    A hybrid model compared 1) standard 12-weeks treatment (no testing), 2) shortened 8-weeks treatment (no testing), and 3) baseline testing with 12-\/8-weeks treatment for those with\/without NS5A polymorphisms from a lifetime Chinese health care payer perspective. All model inputs were retrieved from clinical trials and publically available literature. And sensitivity analyses were also conducted to assess the impact of uncertainty.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Baseline testing was associated with overall increase in total health care cost of USD 13.50 and in QALYs of 0.002 compared with standard 12-weeks treatment (no testing), yielded in an ICER of USD 6750\/QALY gained. Scenario analyses suggested that shortened 8-weeks treatment (no testing) was found to be lower costs and great QALYs compared with other two strategies when the sustained virologic response (SVR) rate increased to 95%. Sensitivity analyses indicated that the results were robust.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Our results suggest prior assessment of NS5A sensitivity followed by optimizing treatment duration was an economic strategy. In addition, shortened 8-weeks treatment (no testing) was shown to be dominant with the SVR rate increased to 95%.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.717504","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:39:11Z","timestamp":1634330351000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir\/Grazoprevir for Chronic Hepatitis C in China"],"prefix":"10.3389","volume":"12","author":[{"given":"Jinyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bin-Chia Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruxu","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","article-title":"Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population","volume":"176","author":"Chahal","year":"2016","journal-title":"JAMA. Intern. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0175189","DOI":"10.1371\/journal.pone.0175189","article-title":"Estimating Cost-Effectiveness Associated with All-Oral Regimen for Chronic Hepatitis C in China","volume":"12","author":"Chen","year":"2017","journal-title":"Plos One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0155934","DOI":"10.1371\/journal.pone.0155934","article-title":"Will Sofosbuvir\/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? an Economic Analysis Using Real-World Data","volume":"11","author":"Chen","year":"2016","journal-title":"Plos One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40261-018-0702-9","article-title":"Cost-Effectiveness of Elbasvir\/Grazoprevir versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in china","volume":"38","author":"Chen","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"B6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/M14-1336","article-title":"Cost-effectiveness and Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir and Ledipasvir in the United States","volume":"162","author":"Chhatwal","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.008","article-title":"Guidelines for the Prevention and Treatment of Hepatitis C (2019 Version)","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1128\/JCM.02407-15","article-title":"Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection","volume":"54","author":"Cloherty","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/hep.24370","article-title":"A Prospective Study of the Rate of Progression in Compensated, Histologically Advanced Chronic Hepatitis C","volume":"54","author":"Dienstag","year":"2011","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.3390\/ijerph18073694","article-title":"Telemedicine Chronic Viral Hepatitis C Treatment during the Lockdown Period in Romania: A Pilot Study","volume":"18","author":"Doica","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/jvh.12639","article-title":"Cost-effectiveness of Elbasvir\/grazoprevir Use in Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Virus Genotype 1 Infection and Chronic Kidney Disease in the United States","volume":"24","author":"Elbasha","year":"2017","journal-title":"J. Viral Hepat."},{"key":"B13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/apt.13882","article-title":"The Cost-Effectiveness of Testing for NS5a Resistance-Associated Polymorphisms at Baseline in Genotype 1a-Infected (Treatment-na\u00efve and Treatment-Experienced) Subjects Treated with All-Oral Elbasvir\/grazoprevir Regimens in the United States","volume":"45","author":"Elbasha","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and Mortality in Compensated Cirrhosis Type C: A Retrospective Follow-Up Study of 384 Patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and Natural History of HCV Infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.3748\/wjg.v22.i19.4615","article-title":"Current Treatment of Chronic Hepatitis C in China: Dilemma and Potential Problems","volume":"22","author":"Han","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/infdis\/jiz154","article-title":"An Open-Label, Randomized, Active-Controlled Trial of 8 versus 12 Weeks of Elbasvir\/Grazoprevir for Treatment-Naive Patients with Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions","volume":"220","author":"Huang","year":"2019","journal-title":"J. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/00004836-200205000-00018","article-title":"Survival and Prognostic Indicators in Patients with Hepatitis B Virus-Related Cirrhosis after Onset of Hepatic Decompensation","volume":"34","author":"Hui","year":"2002","journal-title":"J. Clin. Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0138060","DOI":"10.1371\/journal.pone.0138060","article-title":"Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy","volume":"10","author":"Itakura","year":"2015","journal-title":"Plos One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3111\/13696998.2015.1029492","article-title":"Cost-effectiveness Analysis of Simeprevir in Combination with Peginterferon and Ribavirin for Treatment-Na\u00efve Chronic Hepatitis C Genotype 1 Patients in Japan","volume":"18","author":"Kuwabara","year":"2015","journal-title":"J. Med. Econ."},{"key":"B22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijid.2014.07.003","article-title":"Fibrosis Progression in Interferon Treatment-Naive Chinese Plasma Donors with Chronic Hepatitis C for 20 years: A Cohort Study","volume":"27","author":"Li","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/MEG.0b013e32834dda64","article-title":"Comparison of Survival and Quality of Life of Hepatectomy and Thrombectomy Using Total Hepatic Vascular Exclusion and Chemotherapy Alone in Patients with Hepatocellular Carcinoma and Tumor Thrombi in the Inferior Vena Cava and Hepatic Vein","volume":"24","author":"Liu","year":"2012","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B24","volume-title":"China Guidelines for Pharmacoeconomic Evaluations (2020 Chinese-English Version)","author":"Liu","year":"2020"},{"key":"B25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3389\/fmicb.2019.00535","article-title":"Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in mainland china","volume":"10","author":"Lu","year":"2019","journal-title":"Front. Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"438","DOI":"10.18553\/jmcp.2013.19.6.438","article-title":"The Effect of Hepatitis C Treatment Response on Medical Costs: A Longitudinal Analysis in an Integrated Care Setting","volume":"19","author":"Manos","year":"2013","journal-title":"J. Manag. Care Pharm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0194329","DOI":"10.1371\/journal.pone.0194329","article-title":"Cost-effectiveness Analysis of Elbasvir-Grazoprevir Regimen for Treating Hepatitis C Virus Genotype 1 Infection in Stage 4-5 Chronic Kidney Disease Patients in France","volume":"13","author":"Maunoury","year":"2018","journal-title":"PLOS ONE"},{"key":"B28","unstructured":""},{"key":"B29","volume-title":"China Health Statistical Year Book","year":"2019"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s10198-018-0980-4","article-title":"Economic Evaluation of Zepatier for the Management of HCV in the Italian Scenario","volume":"19","author":"Rolli","year":"2018","journal-title":"Eur. J. Health Econ."},{"key":"B31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of Stage-specific Fibrosis Progression Rates in Chronic Hepatitis C Virus Infection: A Meta-Analysis and Meta-Regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jval.2011.06.006","article-title":"Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis C","volume":"14","author":"Townsend","year":"2011","journal-title":"Value Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.3760\/cma.j.issn.0366-6999.2012.12.014","article-title":"Natural History of Liver Cirrhosis in South China Based on a Large Cohort Study in One center: A Follow-Up Study for up to 5 Years in 920 Patients","volume":"125","author":"Wang","year":"2012","journal-title":"Chin. Med. J. (Engl)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.vhri.2013.02.002","article-title":"A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in china","volume":"2","author":"Wei","year":"2013","journal-title":"Value Health Reg. Issues"},{"key":"B36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jgh.14509","article-title":"Efficacy and Safety of Elbasvir\/grazoprevir in Participants with Hepatitis C Virus Genotype 1, 4, or 6 Infection from the Asia-Pacific Region and Russia: Final Results from the Randomized C-CORAL Study","volume":"34","author":"Wei","year":"","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jgh.14636","article-title":"Safety and Efficacy of Elbasvir\/grazoprevir in Asian Participants with Hepatitis C Virus Genotypes 1 and 4 Infection","volume":"34","author":"Wei","year":"","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/hep.30476","article-title":"The Burden of Chronic Hepatitis C in China from 2004 to 2050: An Individual-Based Modeling Study","volume":"69","author":"Wu","year":"2019","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4254\/wjh.v11.i5.421","article-title":"Hepatitis C Virus Cure with Direct Acting Antivirals: Clinical, Economic, Societal and Patient Value for China","volume":"11","author":"Xie","year":"2019","journal-title":"World J. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s10620-020-06281-8","article-title":"Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in hong kong","volume":"66","author":"Yuen","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e035224","DOI":"10.1136\/bmjopen-2019-035224","article-title":"Cost-utility of Sofosbuvir\/velpatasvir versus Other Direct-Acting Antivirals for Chronic Hepatitis C Genotype 1b Infection in China","volume":"10","author":"Yun","year":"2020","journal-title":"BMJ Open"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.717504\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T20:39:15Z","timestamp":1634330355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.717504\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":39,"alternative-id":["10.3389\/fphar.2021.717504"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.717504","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741088303.793589621","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"article-number":"717504"}}